Beth J Hoffman
CEO Origami Therapeutics, Inc.
Seminars
Thursday 29th October 2026
Phenotypic Screening to Identify & Optimize Protein Degraders for CNS Disorders Acting Through the Autophagy-Lysosome Pathway
1:45 pm
- Keys to designing fruitful phenotypic screens for protein degraders
- Rapid hit prioritization to lead and lead optimization
- Insights into PK/PD for protein degraders
